Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UKIssue Date
2019
Metadata
Show full item recordCitation
McNamara MG, Amir E. Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. Eur J Cancer. 2019 Sep;118:189.Journal
European Journal of CancerDOI
10.1016/j.ejca.2019.05.026PubMed ID
31277809Additional Links
https://dx.doi.org/10.1016/j.ejca.2019.05.026Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2019.05.026
Scopus Count
Collections
Related articles
- Assessing the risk of bias and publication bias should be integral parts of the systematic review.
- Authors: Chen J, Li Y, Zhou X, Li Z, Liu J, Yao Y, Han X
- Issue date: 2019 Sep
- Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
- Authors: Abdel-Rahman OM, Elsayed Z
- Issue date: 2016 Feb 16
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
- Authors: Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z
- Issue date: 2009 Jan
- Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
- Authors: Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao M
- Issue date: 2018 Jul
- Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
- Authors: Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Kim HS, Kim SU, Park MS
- Issue date: 2018 Sep